Calcitonin gene-related peptide monoclonal antibody
Calcitonin gene-related peptide monoclonal antibodies (mAbs) or CGRP mAbs are a new type of preventative migraine treatment. CGRP mAbs block the release of calcitonin gene-related peptide, a neurotransmitter known to cause migraines.
Drugs[edit | edit source]
Currently FDA-licensed CGRP mAbs are:
- Eptinezumab (Vyepti), approved in 2020
- Erenumab (Aimovig), approved in 2018
- Fremanezumab (Ajovy), approved in 2018
- Galcanezumab (Emgality), approved in 2018
Uses[edit | edit source]
News and articles[edit | edit source]
- 2020, Can migraines be untangled by new medical thinking? - The Observer
Learn more[edit | edit source]
- Calcitonin gene-related peptide monoclonal antibodies - The Migraine Trust
- CGRP Medications - Migraine Australia
See also[edit | edit source]
References[edit | edit source]
- "Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies". The Migraine Trust. Retrieved October 12, 2021.
- "What are the new drugs for the treatment of migraines?". Drugs.com. Retrieved October 12, 2021.
- Negro, Andrea; Martelletti, Paolo (June 2019). "Gepants for the treatment of migraine". Expert Opinion on Investigational Drugs. 28 (6): 555–567. doi:10.1080/13543784.2019.1618830. ISSN 1744-7658. PMID 31081399.
- Kang, Seung Ah; Govindarajan, Raghav (2021). "Anti-calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache". Muscle & Nerve. 63 (4): 563–567. doi:10.1002/mus.27153. ISSN 1097-4598.
antagonist A chemical that reduces or helps block the activity of another chemical in the body. For example, most antihistamines are H1 antagonists because they block the H1 histamine receptor, which helps relieve allergy symptoms. The opposite of an agonist.